Filtered By:
Source: The Lancet
This page shows you your search results in order of relevance. This is page number 12.
Order by Relevance | Date
Total 200 results found since Jan 2013.
Thrombus aspiration or retrieval in acute ischaemic stroke
Publication date: 9–15 March 2019Source: The Lancet, Volume 393, Issue 10175Author(s): Bijoy K Menon, Mayank Goyal
Source: The Lancet - March 9, 2019 Category: General Medicine Source Type: research
Late thrombolysis for stroke works, but how do we do it?
Publication date: Available online 22 May 2019Source: The LancetAuthor(s): Shelagh B Coutts, Bijoy K Menon
Source: The Lancet - May 24, 2019 Category: General Medicine Source Type: research
Robotic-assisted training after stroke: RATULS advances science
Publication date: Available online 22 May 2019Source: The LancetAuthor(s): Julie Bernhardt, Jan Mehrholz
Source: The Lancet - May 24, 2019 Category: General Medicine Source Type: research
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial
Publication date: Available online 22 May 2019Source: The LancetAuthor(s): Colin Baigent, Daniel Lasserson, Frank Sullivan, Johanna Carrie, Javier Rojas, Shannon Amoils, John Bamford, Jane Armitage, Gabriel Rinkel, Gordon Lowe, Jonathan Emberson, Karen Innes, Lynn Dinsmore, Jonathan Drever, Carol Williams, David Perry, Connor McGill, David Buchanan, Allan Walker, Aidan HutchisonSummaryBackgroundAntiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial hae...
Source: The Lancet - May 24, 2019 Category: General Medicine Source Type: research
The rise and fall of aspirin in the primary prevention of cardiovascular disease
Publication date: 25–31 May 2019Source: The Lancet, Volume 393, Issue 10186Author(s): Inbar Raber, Cian P McCarthy, Muthiah Vaduganathan, Deepak L Bhatt, David A Wood, John G F Cleland, Roger S Blumenthal, John W McEvoySummaryAspirin is one of the most frequently used drugs worldwide and is generally considered effective for the secondary prevention of cardiovascular disease. By contrast, the role of aspirin in primary prevention of cardiovascular disease is controversial. Early trials evaluating aspirin for primary prevention, done before the turn of the millennium, suggested reductions in myocardial infarction and stro...
Source: The Lancet - May 24, 2019 Category: General Medicine Source Type: research
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
This study is active but not recruiting and is registered with ClinicalTrials.gov, number NCT02706951.FindingsPatients were screened between Feb 23, 2016, and May 19, 2017 and 648 were randomly assigned to treatment. 598 (92%) completed week 14. At week 14, an ACR20 response was achieved by 89 (41%) of 216 patients (95% CI 35–48) in the continued methotrexate group, 147 (68%) of 217 patients (62–74) receiving upadacitinib 15 mg, and 153 (71%) of 215 patients (65–77) receiving upadacitinib 30 mg (p<0·0001 for both doses vs continued methotrexate). DAS28(CRP) 3·2 or lower was met by 42 (19%) of 216 (95% CI 14–2...
Source: The Lancet - May 24, 2019 Category: General Medicine Source Type: research
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Publication date: Available online 9 June 2019Source: The LancetAuthor(s): Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Fady T Botros, Matthew C Riddle, Lars Rydén, Denis Xavier, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Purnima Rao-Melacini, Gloria Wong, Alvaro Avezum, Jan Basile, Namsik Chung, Ignacio CongetSummaryBackgroundTwo glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide...
Source: The Lancet - June 10, 2019 Category: General Medicine Source Type: research
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
This study is registered with ClinicalTrials.gov, number NCT01394952.FindingsBetween Aug 18, 2011, and Aug 14, 2013, 9901 participants (mean age 66·2 years [SD 6·5], median HbA1c 7·2% [IQR 6·6–8·1], 4589 [46·3%] women) were enrolled and randomly assigned to receive dulaglutide (n=4949) or placebo (n=4952). During a median follow-up of 5·4 years (IQR 5·1–5·9), the primary composite outcome occurred in 594 (12·0%) participants at an incidence rate of 2·4 per 100 person-years in the dulaglutide group and in 663 (13·4%) participants at an incidence rate of 2·7 per 100 person-years in the placebo group (hazard ...
Source: The Lancet - June 10, 2019 Category: General Medicine Source Type: research
Sphenopalatine ganglion stimulation after stroke, promising but not yet ready for adoption
Publication date: 20–26 July 2019Source: The Lancet, Volume 394, Issue 10194Author(s): Else Charlotte Sandset, Gary A Ford
Source: The Lancet - July 19, 2019 Category: General Medicine Source Type: research
An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction
Publication date: Available online 1 August 2019Source: The LancetAuthor(s): Zachi I Attia, Peter A Noseworthy, Francisco Lopez-Jimenez, Samuel J Asirvatham, Abhishek J Deshmukh, Bernard J Gersh, Rickey E Carter, Xiaoxi Yao, Alejandro A Rabinstein, Brad J Erickson, Suraj Kapa, Paul A FriedmanSummaryBackgroundAtrial fibrillation is frequently asymptomatic and thus underdetected but is associated with stroke, heart failure, and death. Existing screening methods require prolonged monitoring and are limited by cost and low yield. We aimed to develop a rapid, inexpensive, point-of-care means of identifying patients with atrial ...
Source: The Lancet - August 2, 2019 Category: General Medicine Source Type: research
Uncovering covert stroke in surgical patients
Publication date: Available online 15 August 2019Source: The LancetAuthor(s): Phillip E Vlisides, Michael S Avidan, George A Mashour
Source: The Lancet - August 16, 2019 Category: General Medicine Source Type: research
Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases
In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - August 21, 2019 Category: General Medicine Source Type: research
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Publication date: 24–30 August 2019Source: The Lancet, Volume 394, Issue 10199Author(s): Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi, Karla Hemming, Farin Kamangar, Abdolsamad Gharavi, Mohammad Reza Ostovaneh, Alireza Nateghi, Masoud Majed, Behrooz Navabakhsh, Shahin Merat, Akram Pourshams, Mahdi Nalini, Fatemeh Malekzadeh, Masoumeh Sadeghi, Noushin Mohammadifard, Nizal Sarrafzadegan, Mohammad Naemi-Tabiei, Abdolreza Fazel, Paul BrennanSummaryBackgroundA fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income ...
Source: The Lancet - August 23, 2019 Category: General Medicine Source Type: research
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
We describe the prevalence, hazard ratios (HRs), and population-attributable fractions (PAFs) for cardiovascular disease and mortality associated with a cluster of behavioural factors (ie, tobacco use, alcohol, diet, physical activity, and sodium intake), metabolic factors (ie, lipids, blood pressure, diabetes, obesity), socioeconomic and psychosocial factors (ie, education, symptoms of depression), grip strength, and household and ambient pollution. Associations between risk factors and the outcomes were established using multivariable Cox frailty models and using PAFs for the entire cohort, and also by countries grouped ...
Source: The Lancet - September 3, 2019 Category: General Medicine Source Type: research
Preventing unnecessary disability after stroke in Scotland
Publication date: 5–11 October 2019Source: The Lancet, Volume 394, Issue 10205Author(s): Shelagh B Coutts
Source: The Lancet - October 5, 2019 Category: General Medicine Source Type: research
